Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Watchlist
        Loading...
        US Stock MarketDetailed Quotes
        BIIB Biogen Watchlist
        300.200 -2.210-0.73% Close 06/02 16:00 ET
        300.750+0.550+0.18% Post 18:05 ET
        303.170High297.680Low817.15KVolume
        Post-Market
        • 5D
        • 1D
        • 1W
        • 1M
        • 1Q
        • 1Y

        Company

        Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

        Revenue Breakdown

        Business Unit:USD
        NameYOYOperating income%
        TYSABRI--2.03B19.96%
        SPINRAZA--1.79B17.63%
        Revenues from anti-CD20 therapeutic programs--1.7B16.72%
        TECFIDERA--1.44B14.19%
        AVONEX--973.5M9.57%
        VUMERITY--553.4M5.44%
        Other revenues--485.1M4.77%
        BENEPALI--441M4.33%
        other--419.7M4.13%
        PLEGRIDY--331.9M3.26%
        View all

        Comments

        Read more
        Paper Trade Start
        Symbol
        Direction
        Buy
        Sell
        Types
        LMT Order
        Price
        QTY
        Amount
        --